FDA Restrictions on Mifepristone: Time for a Change?

Loading...
Thumbnail Image
Penn collection
Issue Briefs
Degree type
Discipline
Subject
miscarriage
mifepristone
fda
pregnancy
pregnant
trimester
Health Economics
Health Policy
Maternal and Child Health
Obstetrics and Gynecology
Women's Health
Funder
Grant number
Copyright date
Distributor
Author
Weiner, Janet
Schreiber, Courtney A.
Contributor
Abstract

Mifepristone, a drug used to manage early miscarriage or end an early pregnancy, carries unique restrictions imposed by the U.S. Food and Drug Administration (FDA). Patients are required to pick up the drug in person from a doctor or a clinic, even though they can take the drug at home. In July, a federal court ruled that the FDA must suspend these restrictions during the COVID-19 pandemic, for patients seeking an early abortion, although the ruling did not apply to women with an early pregnancy loss. But the challenges to FDA restrictions on mifepristone predate the pandemic. This Issue Brief provides the context for this ongoing controversy, and reviews recent evidence on the clinical and cost effectiveness of mifepristone for the medical management of first trimester miscarriage.

Advisor
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Publication date
2020-09-10
Volume number
Issue number
Publisher
Publisher DOI
Journal Issue
Comments
Recommended citation
Collection